Skip to main content
Corvus Pharmaceuticals, Inc. logo

Corvus Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · CRVS ISIN · US2210151005 LEI · 549300I3AVJ8F75NCX65 US Manufacturing
Open in API
Filings indexed 552 across all filing types
Latest filing 2026-05-14 Regulatory Filings
Country US United States of America
Listing US CRVS

About Corvus Pharmaceuticals, Inc.

https://www.corvuspharma.com/

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops novel therapies for immune diseases and cancer. The company focuses on pioneering ITK (Interleukin-2-inducible T-cell kinase) inhibition as a new approach to modulate and control signaling pathways within the immune system. Its lead product candidate, soquelitinib, is a first-in-class, oral therapy that selectively inhibits ITK and is being developed for the treatment of T-cell lymphomas and other immune-related conditions. Corvus is advancing a pipeline of clinical-stage programs with differentiated mechanisms of action designed to precisely target critical immune pathways.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 89% confidence The document is a U.S. SEC Form 8-K (Current Report) by Corvus Pharmaceuticals, containing Regulation FD Disclosure (Item 7.01) and Other Events (Item 8.01) reporting a furnished press release and clinical-trial data. It is a regulatory compliance filing rather than an earnings release, financial report, or management presentation, and does not fall into a more specific category. Therefore, it should be classified under Regulatory Filings (RNS).
2026-05-14 English
S-8 - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)
Share Issue/Capital Change Classification · 90% confidence The document is a Registration Statement on Form S-8 filed with the SEC to register shares issuable under the company’s 2016 Equity Incentive Award Plan. Form S-8 is specifically used to register new share issuances under employee benefit plans, making this a capital change/share issue filing. This matches the definition for Share Issue/Capital Change (Code: SHA).
2026-05-07 English
SCHEDULE 13G/A - Corvus Pharmaceuticals, Inc. (0001626971) (Subject)
Major Shareholding Notification
2026-03-26 English
SCHEDULE 13D/A Filing
Major Shareholding Notification
2026-02-05 English
SCHEDULE 13G Filing
Major Shareholding Notification
2026-01-30 English
4 Filing
Director's Dealing
2026-01-30 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.